Definium Therapeutics reported top-line results from a Phase 3 trial of DT-120 (lysergide, LSD) in major depressive disorder, saying the single-dose therapy significantly improved depression scores versus placebo. The company highlighted a 13.3-point drop on the MADRS scale versus 5.2 points with placebo at six weeks. Definium also reported the effect was largely maintained at 12 weeks, with patients on DT-120 showing an 11-point reduction from baseline compared with 3.6 in the placebo arm. The update positions the program closer to potential regulatory review. For the category, the readout reinforces investor appetite for psychedelic-assisted therapeutics with late-stage efficacy potential, while increasing scrutiny on durability, safety, and trial controls as companies prepare for follow-on registrational steps.